Abstract

AH Mansur: Received speaker fees and payment (including gifts or other consideration or ‘in kind’ compensation) through attending advisory board meeting to various companies including Novatis, Roche, AstraZeneca, NAPP, BI; Received educational grants for service development from Novartis pharmaceuticals; Participated in Phase IIb and III clinical trials with AstraZeneca, Novartis, Roche

GT Ferguson: Received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Pearl Therapeutics; Served on board or advisory committee for AstraZeneca, Pearl Therapeutics, and Novartis; Received research support from AstraZeneca, Boehringer Ingelheim, Pearl Therapeutics, Sunovion, Novartis, and Theravance

JS Jacobs: Speaker/Teacher for Shire, Teva; Clinical Investigator for CSL Behring, Genentech, Regeneron, Sanofi, Shire, and Teva; Acted on Advisory committee for CSL Behring, Pharming Group, and Regeneron; Served as Independent Contractor for Genentech, CSL Behring, Regeneron, and Teva

J Hebert: Consultant: Novartis, Merck, Teva, CSL Behring, Baxter, Shire; Conference Speaker: Merck, Novartis, Shire, Meda, CSL Behring; Investigator in clinical trials: Merck, Novartis, Stallergenis, GSK, Boehringer Ingelheim, CSL Behring, DBV

C Clawson: Employee of MedImmune; Holds stock in AstraZeneca

W Tao: Employee of AstraZeneca

Y Wu: Employee of AstraZeneca

M Goldman: Employee of AstraZeneca